1794811-52-1
1794811-52-1
Chemical Structure
Moxonidine-d4
- CAS No.: 1794811-52-1
- Formula:C9H8D4ClN5O
- Molecular Weight:245.70
IUPAC Name: 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl-4,4,5,5-d4)-6-methoxy-2-methylpyrimidin-5-amine
InChIKey: WPNJAUFVNXKLIM-KHORGVISSA-N
SMILES: N(C=1C(OC)=NC(C)=NC1Cl)C=2NC(C(N2)([2H])[2H])([2H])[2H]
Biological Activity: Moxonidine-d4 (BDF5895-d4) is the deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Moxonidine-d4 | Moxonidine-d4 (BDF5895-d4) is the deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxonidine (Standard) | ≥98% | Moxonidine (Standard) is the analytical standard of Moxonidine (HY-B0374). This product is intended for research and analytical applications. Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxonidine-d7 | Moxonidine-d7 is deuterated labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxonidine-d3 | Moxonidine-d3 (BDF5895-d3) is deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxonidine-133 | Moxonidine-13C,d3 (BDF5895-13C,d3) is the 13C-labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an imidazoline type 1 receptor (I1-R) selective agonist and antihypertensive agent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxonidine | 99.72% | Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Aceros H, et al. Moxonidine modulates cytokine signalling and effects on cardiac cell viability. Eur J Pharmacol. 2014 Oct 5;740:168-82. [Content Brief]
- [3]. Wang Y, et al. Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice. Int J Mol Sci. 2023 Feb 14;24(4):3857. [Content Brief]
- [4]. Kim YH, et al. Modulation of N-type Ca²⁺ currents by moxonidine via imidazoline I₁ receptor activation in rat superior cervical ganglion neurons. Biochem Biophys Res Commun. 2011 Jun 17;409(4):645-50. [Content Brief]
- [5]. Zhu QM, et al. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126(6):1522-30. [Content Brief]
- [6]. Van Kerckhoven R, et al. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur J Pharmacol. 2000 May 26;397(1):113-20. [Content Brief]
- [7]. Nurminen ML, et al. Effect of moxonidine on blood pressure and sympathetic tone in conscious spontaneously hypertensive rats. Eur J Pharmacol. 1998 Nov 27;362(1):61-7. [Content Brief]
- [8]. Tsutsui H, et al. Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol. 2009 Jan 28;603(1-3):73-8. [Content Brief]
